ATE346609T1 - Kombinierte meningitis b/c impfstoffe - Google Patents

Kombinierte meningitis b/c impfstoffe

Info

Publication number: ATE346609T1
Authority: AT; Austria
Prior art keywords: vaccines; meningitis; combined; combined meningitis; serogroup
Prior art date: 1998-05-29

Application number

AT99926046T

Other languages

English (en)

Inventor

Dan M Granoff

Ingeborg S Aaberge

Bjorn Haneberg

Johan Holst

Howard Raff

Original Assignee

Novartis Vaccines & Diagnostic

Statens Inst For Folkehelse

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-29

Filing date

1999-05-28

Publication date

2006-12-15

1999-05-28 Application filed by Novartis Vaccines & Diagnostic, Statens Inst For Folkehelse filed Critical Novartis Vaccines & Diagnostic

2006-12-15 Application granted granted Critical

2006-12-15 Publication of ATE346609T1 publication Critical patent/ATE346609T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Beans For Foods Or Fodder (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99926046T 1998-05-29 1999-05-28 Kombinierte meningitis b/c impfstoffe ATE346609T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8735198P	1998-05-29	1998-05-29
US10644698P	1998-10-30	1998-10-30

Publications (1)

Publication Number	Publication Date
ATE346609T1 true ATE346609T1 (de)	2006-12-15

Family

ID=26776879

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99926046T ATE346609T1 (de)	1998-05-29	1999-05-28	Kombinierte meningitis b/c impfstoffe

Country Status (14)

Country	Link
US (1)	US8007815B1 (de)
EP (2)	EP2796148A3 (de)
JP (2)	JP5074644B2 (de)
AT (1)	ATE346609T1 (de)
AU (2)	AU761495B2 (de)
BR (1)	BR9910749A (de)
CA (1)	CA2332963C (de)
CY (1)	CY1107550T1 (de)
DE (1)	DE69934225T2 (de)
DK (1)	DK1079857T3 (de)
ES (2)	ES2278446T3 (de)
NZ (1)	NZ508771A (de)
PT (2)	PT1079857E (de)
WO (1)	WO1999061053A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2298900A1 (de)	1996-09-17	2011-03-23	Novartis Vaccines and Diagnostics, Inc.	Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
WO1999061053A1 (en)	1998-05-29	1999-12-02	Chiron Corporation	Combination meningitidis b/c vaccines
NZ515935A (en)	1999-05-19	2004-01-30	Chiron S	Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
GB9928196D0 (en) *	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
PT2289545T (pt) *	2000-01-17	2016-09-06	Glaxosmithkline Biologicals Sa	Vacina de omv suplementada contra meningococos
ES2519440T3 (es)	2000-07-27	2014-11-07	Children's Hospital & Research Center At Oakland	Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
ATE469915T1 (de)	2001-07-27	2010-06-15	Novartis Vaccines & Diagnostic	Antikörper gegen das meningokokken adhäsin app
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en)	2003-07-15	2003-08-20	Chiron Srl	Vesicle filtration
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
GB0419627D0 (en)	2004-09-03	2004-10-06	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
WO2006081259A2 (en)	2005-01-27	2006-08-03	Children's Hospital & Research Center At Oakland	Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
BR122016015627A2 (pt) *	2007-10-19	2018-10-30	Novartis Ag	kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
CN102596240B (zh) *	2009-08-27	2015-02-04	诺华股份有限公司	包括脑膜炎球菌fHBP序列的杂交多肽
CN107913396B (zh)	2010-08-23	2022-03-08	惠氏有限责任公司	脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
GB201015132D0 (en) *	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
US9259462B2 (en)	2010-09-10	2016-02-16	Glaxosmithkline Biologicals Sa	Developments in meningococcal outer membrane vesicles
AU2011300409B2 (en)	2010-09-10	2015-03-26	Wyeth Llc	Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
MY198910A (en)	2012-03-09	2023-10-02	Pfizer	Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6324961B2 (ja) *	2012-09-06	2018-05-16	ノバルティスアーゲー	血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
JP6283674B2 (ja)	2012-09-18	2018-02-21	グラクソスミスクラインバイオロジカルズソシエテアノニム	外膜小胞
WO2014136064A2 (en)	2013-03-08	2014-09-12	Pfizer Inc.	Immunogenic fusion polypeptides
RU2662968C2 (ru)	2013-09-08	2018-07-31	Пфайзер Инк.	Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en)	2015-02-19	2016-08-25	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en)	2017-01-31	2022-03-17	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
WO2021059181A1 (en)	2019-09-27	2021-04-01	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2848965A1 (de)	1978-11-11	1980-05-22	Behringwerke Ag	Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) *	1985-09-17	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
EP0449958B9 (de) *	1988-12-19	2003-05-28	American Cyanamid Company	Meningococcales klasse i-aussenmembranprotein-vakzin
US7118757B1 (en) *	1988-12-19	2006-10-10	Wyeth Holdings Corporation	Meningococcal class 1 outer-membrane protein vaccine
CA2017507C (en)	1989-05-25	1996-11-12	Gary Van Nest	Adjuvant formulation comprising a submicron oil droplet emulsion
EP0624376B1 (de)	1993-05-13	2000-03-15	American Cyanamid Company	Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
ATE173634T1 (de)	1994-04-20	1998-12-15	Us Army	Impfstoff gegen gram-negative bakterielle infektionen
US6180111B1 (en)	1995-05-18	2001-01-30	University Of Maryland	Vaccine delivery system
CN1211192A (zh) *	1995-09-18	1999-03-17	美国陆军医疗材料研究指挥部	生产非共价复合的多价蛋白体亚基疫苗的改进方法
DE19601754A1 (de) *	1996-01-19	1997-07-24	Hoechst Ag	Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) *	1996-04-18	1998-12-08	University Of Iowa Research Foundation	Hepatitis C virus Fc-binding function
ES2166097T5 (es) *	1996-08-27	2007-03-16	Novartis Vaccines And Diagnostics, Inc.	Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
US6558677B2 (en) *	1996-10-15	2003-05-06	Wendell D. Zollinger	Vaccine against gram negative bacteria
WO1998058670A1 (en) *	1997-06-24	1998-12-30	Chiron Corporation	Methods of immunizing adults using anti-meningococcal vaccine compositions
CA2297072A1 (en) *	1997-07-17	1999-01-28	Baxter Healthcare S.A.	Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
WO1999061053A1 (en)	1998-05-29	1999-12-02	Chiron Corporation	Combination meningitidis b/c vaccines
AU1917501A (en)	1999-11-12	2001-06-06	University Of Iowa Research Foundation, The	Control of neisserial membrane synthesis
ES2519440T3 (es)	2000-07-27	2014-11-07	Children's Hospital & Research Center At Oakland	Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
EP2172213B1 (de)	2003-01-30	2013-04-03	Novartis AG	Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
GB0316560D0 (en)	2003-07-15	2003-08-20	Chiron Srl	Vesicle filtration
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups

1999
- 1999-05-28 WO PCT/US1999/011977 patent/WO1999061053A1/en not_active Ceased
- 1999-05-28 EP EP20140169154 patent/EP2796148A3/de not_active Withdrawn
- 1999-05-28 PT PT99926046T patent/PT1079857E/pt unknown
- 1999-05-28 AU AU42215/99A patent/AU761495B2/en not_active Revoked
- 1999-05-28 CA CA2332963A patent/CA2332963C/en not_active Expired - Fee Related
- 1999-05-28 ES ES99926046T patent/ES2278446T3/es not_active Expired - Lifetime
- 1999-05-28 AT AT99926046T patent/ATE346609T1/de active
- 1999-05-28 JP JP2000550512A patent/JP5074644B2/ja not_active Expired - Fee Related
- 1999-05-28 ES ES06076647.4T patent/ES2485940T3/es not_active Expired - Lifetime
- 1999-05-28 DK DK99926046T patent/DK1079857T3/da active
- 1999-05-28 PT PT60766474T patent/PT1741443E/pt unknown
- 1999-05-28 DE DE69934225T patent/DE69934225T2/de not_active Expired - Lifetime
- 1999-05-28 US US09/701,453 patent/US8007815B1/en not_active Expired - Fee Related
- 1999-05-28 NZ NZ508771A patent/NZ508771A/en not_active IP Right Cessation
- 1999-05-28 EP EP99926046A patent/EP1079857B1/de not_active Expired - Lifetime
- 1999-05-28 BR BR9910749-0A patent/BR9910749A/pt not_active Application Discontinuation
2003
- 2003-09-02 AU AU2003244518A patent/AU2003244518A1/en not_active Withdrawn
2007
- 2007-01-31 CY CY20071100128T patent/CY1107550T1/el unknown
2009
- 2009-09-24 JP JP2009219818A patent/JP2009292851A/ja active Pending

Also Published As

Publication number	Publication date
EP2796148A2 (de)	2014-10-29
DE69934225T2 (de)	2007-09-27
EP2796148A3 (de)	2015-02-25
EP1079857A1 (de)	2001-03-07
AU4221599A (en)	1999-12-13
DK1079857T3 (da)	2007-01-29
US8007815B1 (en)	2011-08-30
ES2485940T3 (es)	2014-08-14
CA2332963A1 (en)	1999-12-02
JP2009292851A (ja)	2009-12-17
HK1034460A1 (en)	2001-10-26
NZ508771A (en)	2003-08-29
ES2278446T3 (es)	2007-08-01
DE69934225D1 (de)	2007-01-11
PT1079857E (pt)	2007-02-28
WO1999061053A1 (en)	1999-12-02
AU2003244518A1 (en)	2003-09-25
BR9910749A (pt)	2001-02-13
CA2332963C (en)	2013-07-23
EP1079857B1 (de)	2006-11-29
JP2002516292A (ja)	2002-06-04
CY1107550T1 (el)	2013-03-13
PT1741443E (pt)	2014-07-31
JP5074644B2 (ja)	2012-11-14
AU761495B2 (en)	2003-06-05

Legal Events

Date

Code

Title

Description

2007-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1079857

Country of ref document: EP

Publication	Publication Date	Title
DE69934225D1 (de)	2007-01-11	Kombinierte meningitis b/c impfstoffe
NO20022531L (no)	2002-07-12	Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
LU91734I2 (fr)	2011-03-14	Menveo - oligosaccharide méningococcique du group Y conjugué à la protéine CRM197 de Corynebacteriumdiphteriae.
FI912965A0 (fi)	1991-06-18	Vaccin innehaollande protein fraon klass 1-yttermembranen av meningokocker.
ATE500843T1 (de)	2011-03-15	Streptococcus pneumoniae proteine und impfstoffe
BR0107972A (pt)	2002-11-05	Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
HUP0400719A2 (hu)	2004-07-28	Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
HUP0301180A2 (hu)	2004-03-01	Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
ATE347376T1 (de)	2006-12-15	Behandlung von allergien
PT998287E (pt)	2003-09-30	Utilizacao de levobupivacaina
DK1265577T3 (da)	2004-03-15	Medicinsk eller dentalmedicinsk behandlingsstol
DK1112747T3 (da)	2004-10-25	Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
EP1741443A3 (de)	2007-02-28	Kombinierte Meningitis B/C Impfstoffe
ATE334697T1 (de)	2006-08-15	Boviner atmungs- und darmcoronavirus als impfstoff
CY1106092T1 (el)	2011-06-08	Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2
DE69824794D1 (de)	2004-08-05	Streptococcus equi Impfstoff
ITTO20020284A1 (it)	2003-09-29	Procedimento per la sterilizzazione e la neutralizzazione di odori dell'aria.
DK1626726T3 (da)	2006-12-27	Anvendelse af lornoxicam eller lornoxicam-analoger
NZ523676A (en)	2003-03-28	Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease
ES2127133B1 (es)	1999-12-01	Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.